IGNITE data overview
| Treatment differences (QVA149 vs comparator) | |||||||
|---|---|---|---|---|---|---|---|
| Parameters | Study (N) | PBO | IND | GLY | TIO | SFC | |
| Lung function | SPARK (2224) | Trough FEV1, mL | - | - | 70*** | 60*** | - |
| SHINE (2144) | 200*** | 70*** | 90*** | 80*** | - | ||
| FEV1 AUC0−12h, mL | 330*** | 130*** | 130*** | 120*** | - | ||
| ILLUMINATE (523) | - | - | - | - | 140*** | ||
| BLAZE (247) | FEV1 AUC0−4h, mL | 250*** | - | - | 90*** | - | |
| Dyspnoea | TDI score | 1.37*** | - | - | 0.49* | - | |
| ILLUMINATE | - | - | - | - | 0.76** | ||
| Health status | SPARK | SGRQ score | - | - | −2.07*** | −2.69*** | - |
| Rate reduction of exacerbations, % | Moderate-to-severe | - | - | 12 RR 0.88* | 10 RR 0.90 | - | |
| All | - | - | 15 RR 0.85*** | 14 RR 0.86** | - | ||
| ILLUMINATE | Moderate-to-severe | - | - | - | - | 20 RR 0.80 | |
| All | - | - | - | - | 31 RR 0.69 | ||
↵* p<0.05;** p<0.01; *** p≤0.001; †free combination; GLY=glycopyrronium; IND=indacaterol; PBO=placebo; SFC=salmeterol/fluticasone; RR=rate ratio;TIO=tiotropium